Labopharm Inc. (TSX:DDS) today announced that it has received regulatory approval for its once-daily tramadol product for 22 countries under the Mutual Recognition Procedure (MRP). As part of the MRP process, the Company has reached agreement with these countries on a common product label. Approval under MRP directs these countries to issue Marketing Authorization with the common product label in due course. The Company expects to receive Marketing Authorizations from individual countries beginning within the next 30 days and continuing into the first half of 2006.
Canada NewsWire Group (http://www.newswire.ca/en/releases/archive/September2005/06/c5947.html)